Markets:

Overview

News

Currencies

International

Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

64.66 -0.42 (-0.65%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Here's Why Arrowhead Pharmaceuticals Stock Is Getting Hammered Today ↗

July 02, 2021

A paused clinical trial with an important asset wasn't what investors wanted to hear today.

Via The Motley Fool

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 02, 2021

Gainers Alector (NASDAQ:ALEC) stock moved upwards by 39.93% to $31.36 during Friday's pre-market session. The market value of their outstanding shares is at $2.5...

Via Benzinga

Arrowhead Stock Drops After RNAi Therapeutic Shows Lung Inflammation In Animal Models ↗

July 02, 2021

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has voluntarily paused the AROENaC1001 Phase 1/2 study evaluating ARO-ENaC for cystic fibrosis. ARO-ENaC is the...

Via Benzinga

Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study

July 02, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia

June 30, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress

June 26, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress

June 25, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO ↗

June 24, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ...

Via Benzinga

Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress

June 23, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Horizon Acquires Rights to Arrowhead's RNAi-Based Gout Treatment Candidate ↗

June 21, 2021

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) have entered into a global collaboration and license agreement ...

Via Benzinga

Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout

June 21, 2021

From Arrowhead Pharmaceuticals, Inc. and Horizon Therapeutics plc

Via Business Wire

The Week In Charts - Why You Can't Trade, Or Maybe You Can? ↗

June 18, 2021

In this video, I look at the reasons for why you may or may not be able to trade. I also continue my discussion on finding

Via Talk Markets

Biotech Movers During ASCO Week ↗

June 12, 2021

The biotech sector performed well in a good ASCO week. And many biotech stocks were movers this week as a bullish sentiment took hold sparked by the Biogen Aduhelm approval.

Via Talk Markets

Vertex Pharma Stumbles In Rare-Disease Effort, Buoying Rival Arrowhead Pharma ↗

June 10, 2021

Vertex Pharmaceuticals scrapped development of a rare-disease treatment Thursday that appeared unlikely to benefit patients, and VRTX stock plunged.

Via Investor's Business Daily

Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia

June 03, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences

June 02, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Receives $10M Option Exercise Fee From Janssen ↗

May 18, 2021

Janssen Pharmaceuticals Inc, part of Johnson & Johnson (NYSE: JNJ), has delivered written notice of its intent to exercise its option right for ARO-JNJ1....

Via Benzinga

Arrowhead Earns $10 Million Option Exercise Fee

May 18, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences

May 12, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Pharmaceuticals, Inc (ARWR) Q2 2021 Earnings Call Transcript ↗

May 05, 2021

ARWR earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results

May 04, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data ↗

May 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Arrowhead's ARO-AAT Treatment Associated With Improved Fibrosis In Patients With Alpha-1 Liver Disease ↗

April 28, 2021

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced positive interim 48-week liver biopsy results from the Phase 2 AROAAT2002 study ...

Via Benzinga

Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease

April 28, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results

April 16, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform

April 15, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.